A number of publicly traded drug companies have more than tripled their forecast net profits for the first three quarters.

Recently, a share listed companies in the first three quarters of the performance forecast has come out, a number of pharmaceutical biological companies' performance "pre-pleased". Flush data show, as of press release, A share pharmaceutical and biological industry (Shenwan industry classification) a total of nine companies disclosed the first three quarters of performance forecast, eight net profit is expected to achieve year-on-year growth, an essentially flat.

Specifically, Wantai Biochem, Kapur Biochem and Wuxi Apptec are temporarily in the top three in terms of pre-tax net profit growth, with the upper limit of the change range exceeding 100%.Nano Technology, Kelun Pharmaceutical, Zoli Pharmaceutical and Huahai Pharmaceutical are expected to sustain double-digit net profit growth, while East China Pharmaceutical is expected to maintain single-digit net profit growth.In addition, Wuhan Pharmaceutical is expected to report net revenue translation of -10.00% to -10.00%, with results expected to be essentially flat.

Wantai Bio announced on October 12 that it expects to achieve net profit attributable to the parent company of 3.75 billion yuan to 3.95 billion yuan for the first three quarters of this year, an increase of 216.00 percent year-on-year to 232.00 percent;;It is expected to realize non-net profit of 3.650 billion yuan to 3.850 billion yuan, an increase of 216.00 percent to 233.00 percent. The company cited continued strong production and sales of its bivalent cervical cancer vaccine, as well as high revenue and earnings growth, as the main reasons for the increase.

In vitro diagnostics, Capex Biotech and medical research and development outsourcing, Wuxi Apptec are also expected to post high net profit. For the first three quarters of this year, net profit attributable to shareholders of listed companies is expected to reach 1.350 billion yuan to 1.450 billion yuan, an increase of 108.68 percent to 124.14 percent; Wuxi Apptec expects to achieve revenue of about 28.395 billion yuan in the first three quarters of this year, up about 71.87 percent year on year, and net profit attributable to the company's shareholders of about 7.378 billion yuan, up about 107.12 percent year on year. The reporter also noted that after updating the full-year performance target in July this year, the 2022 full-year revenue growth target was raised from 65%-70% to 68%-72%, wuxi Apptec said in the "first three quarters of 2022 results advance announcement" that the company was confident of achieving the 2022 full-year revenue growth target of 68%-72%.

Zhongtai Securities entered the performance disclosure period in October in order to actively capture the apparent growth in quick-moving stocks that may exceed expectations. Guosen securities, said A shares is about to enter three quarterly results revealed dense phase, expected to CXO and some of the medical devices sector companies will continue to peak growth performance, blood products, such as traditional Chinese medicine sector is expected to have robust growth, and medical services, chemical pharmaceutical sector performance affected by outbreaks and in, looking forward to the follow-up results.